SOCS-1 binding to tyrosine 441 of IFN-gamma receptor subunit 1 contributes to the attenuation of IFN-gamma signaling in vivo. 2009

Robyn Starr, and Martina Fuchsberger, and Lei Shong Lau, and Adam P Uldrich, and Ankita Goradia, and Tracy A Willson, and Anne M Verhagen, and Warren S Alexander, and Mark J Smyth
Signal Transduction Laboratory, St Vincent's Institute, 9 Princes Street, Fitzroy, Victoria 3065, Australia. rstarr@svi.edu.au

Suppressor of cytokine signaling (SOCS)-1 is a critical inhibitor of IFN-gamma signal transduction in vivo, but the precise biochemical mechanism of action of SOCS-1 is unclear. Studies in vitro have shown that SOCS-1 binds to Jaks and inhibits their catalytic activity, but recent studies indicate SOCS-1 may act in a similar manner to SOCS-3 by firstly interacting with cytokine receptors and then inhibiting Jak activity. Here, we have generated mice, termed Ifngr1(441F), in which a putative SOCS-1 binding site, tyrosine 441 (Y441), on the IFN-gamma receptor subunit 1 (IFNGR1) is mutated. We confirm that SOCS-1 binds to IFNGR1 in wild-type but not mutant cells. Mutation of Y441 results in impaired negative regulation of IFN-gamma signaling. IFN-gamma-induced STAT1 activation is prolonged in Ifngr1(441F) cells, but not to the extent seen in cells completely lacking SOCS-1, suggesting that SOCS-1 maintains activity to modulate IFN-gamma signaling via other mechanisms. Despite this, we show that hypersensitivity to IFN-gamma results in enhanced innate tumor protection in Ifngr1(441F) mice in vivo, and unregulated expression of an IFN-gamma-dependent chemokine, monokine-induced by IFN-gamma. Collectively, these data indicate that Y441 contributes to the regulation of signaling through IFNGR1 via the recruitment of SOCS-1 to the receptor.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D000071222 Suppressor of Cytokine Signaling 1 Protein A suppressor of cytokine signaling protein that consists of an N-terminal kinase-inhibitory region, a central SH2 DOMAIN, a characteristic C-terminal SOCS box (a 40-amino acid motif, which functions to recruit E3 UBIQUITIN-PROTEIN LIGASE COMPLEXES). SOCS1 functions as a negative regulator of CYTOKINES that signal through the JANUS KINASES-STAT 3 TRANSCRIPTION FACTOR (JAK/STAT3) pathway by inhibiting the activity of JANUS KINASES. SOCS1 Protein,Suppressor of Cytokine Signaling Protein 1 -,Protein, SOCS1,Suppressor of Cytokine Signaling Protein 1
D000096743 Interferon gamma Receptor A heterodimeric receptor composed of two subunits IFNGR1 and IFNGR2. Activated IFNGR1 subunit is believed to form a docking site for SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1). IFNGR2 associates with IFNGR1 to form a receptor for the cytokine interferon gamma (IFNG). CD119 Antigen,CDw119 Antigen,IFN-gamma Receptor 1,IFNGR2 Protein,Interferon gamma Receptor 2,Interferon gamma Receptors,Receptor, Interferon gamma,IFN-gammaR,1, IFN-gamma Receptor,Antigen, CD119,Antigen, CDw119,IFN gamma Receptor 1,IFN gammaR,Protein, IFNGR2,Receptor 1, IFN-gamma,Receptors, Interferon gamma,gamma Receptor, Interferon,gamma Receptors, Interferon
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Robyn Starr, and Martina Fuchsberger, and Lei Shong Lau, and Adam P Uldrich, and Ankita Goradia, and Tracy A Willson, and Anne M Verhagen, and Warren S Alexander, and Mark J Smyth
January 2005, The Journal of biological chemistry,
Robyn Starr, and Martina Fuchsberger, and Lei Shong Lau, and Adam P Uldrich, and Ankita Goradia, and Tracy A Willson, and Anne M Verhagen, and Warren S Alexander, and Mark J Smyth
September 2011, The Journal of biological chemistry,
Robyn Starr, and Martina Fuchsberger, and Lei Shong Lau, and Adam P Uldrich, and Ankita Goradia, and Tracy A Willson, and Anne M Verhagen, and Warren S Alexander, and Mark J Smyth
November 2006, Journal of leukocyte biology,
Robyn Starr, and Martina Fuchsberger, and Lei Shong Lau, and Adam P Uldrich, and Ankita Goradia, and Tracy A Willson, and Anne M Verhagen, and Warren S Alexander, and Mark J Smyth
September 2014, Cellular and molecular life sciences : CMLS,
Robyn Starr, and Martina Fuchsberger, and Lei Shong Lau, and Adam P Uldrich, and Ankita Goradia, and Tracy A Willson, and Anne M Verhagen, and Warren S Alexander, and Mark J Smyth
April 2006, The Journal of biological chemistry,
Robyn Starr, and Martina Fuchsberger, and Lei Shong Lau, and Adam P Uldrich, and Ankita Goradia, and Tracy A Willson, and Anne M Verhagen, and Warren S Alexander, and Mark J Smyth
May 2001, Immunity,
Robyn Starr, and Martina Fuchsberger, and Lei Shong Lau, and Adam P Uldrich, and Ankita Goradia, and Tracy A Willson, and Anne M Verhagen, and Warren S Alexander, and Mark J Smyth
September 1998, The Journal of biological chemistry,
Robyn Starr, and Martina Fuchsberger, and Lei Shong Lau, and Adam P Uldrich, and Ankita Goradia, and Tracy A Willson, and Anne M Verhagen, and Warren S Alexander, and Mark J Smyth
May 2009, Blood,
Robyn Starr, and Martina Fuchsberger, and Lei Shong Lau, and Adam P Uldrich, and Ankita Goradia, and Tracy A Willson, and Anne M Verhagen, and Warren S Alexander, and Mark J Smyth
July 2007, British journal of cancer,
Robyn Starr, and Martina Fuchsberger, and Lei Shong Lau, and Adam P Uldrich, and Ankita Goradia, and Tracy A Willson, and Anne M Verhagen, and Warren S Alexander, and Mark J Smyth
May 2006, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!